about
Rapid chemotherapy-induced acute endothelial progenitor cell mobilization: implications for antiangiogenic drugs as chemosensitizing agents.Activity of combination chemotherapy in brain metastases from breast and lung adenocarcinoma.Proposed new clinicopathological surrogate definitions of luminal A and luminal B (HER2-negative) intrinsic breast cancer subtypesIs chemotherapy necessary for premenopausal women with lower-risk node-positive, endocrine responsive breast cancer? 10-year update of International Breast Cancer Study Group Trial 11-93Lessons from the Fourth Metronomic and Anti-angiogenic Therapy Meeting, 24-25 June 2014, Milan.Classical cyclophosphamide, methotrexate, and fluorouracil chemotherapy is more effective in triple-negative, node-negative breast cancer: results from two randomized trials of adjuvant chemoendocrine therapy for node-negative breast cancer.Timing of radiotherapy and outcome in patients receiving adjuvant endocrine therapy.Analyses adjusting for selective crossover show improved overall survival with adjuvant letrozole compared with tamoxifen in the BIG 1-98 study.Adjuvant systemic therapies for patients with breast cancer: endocrine responsiveness and effects of chemotherapy.Benefits and adverse effects of endocrine therapySystemic treatments for women with breast cancer: outcome with relation to screening for the disease.Long-term results of International Breast Cancer Study Group Trial VIII: adjuvant chemotherapy plus goserelin compared with either therapy alone for premenopausal patients with node-negative breast cancer.Which patients benefit most from adjuvant aromatase inhibitors? Results using a composite measure of prognostic risk in the BIG 1-98 randomized trial.Preoperative systemic treatment: prediction of responsiveness.Improved adjuvant endocrine therapy for premenopausal women with endocrine responsive diseaseInternational guidelines for management of metastatic breast cancer: can metastatic breast cancer be cured?Adjuvant therapy for very young women with breast cancer: response according to biologic and endocrine features.Circulating endothelial-cell kinetics and viability predict survival in breast cancer patients receiving metronomic chemotherapyLong-term results of intrapericardial chemotherapeutic treatment of malignant pericardial effusions with thiotepa.Patient-reported outcomes with adjuvant exemestane versus tamoxifen in premenopausal women with early breast cancer undergoing ovarian suppression (TEXT and SOFT): a combined analysis of two phase 3 randomised trials.Low-Dose Oral Cyclophosphamide and Methotrexate Maintenance for Hormone Receptor-Negative Early Breast Cancer: International Breast Cancer Study Group Trial 22-00.Adjuvant endocrine therapy for premenopausal women with early breast cancer.Outcomes of special histotypes of breast cancer after adjuvant endocrine therapy with letrozole or tamoxifen in the monotherapy cohort of the BIG 1-98 trial.Obesity and risk of recurrence or death after adjuvant endocrine therapy with letrozole or tamoxifen in the breast international group 1-98 trial.Treatment Efficacy, Adherence, and Quality of Life Among Women Younger Than 35 Years in the International Breast Cancer Study Group TEXT and SOFT Adjuvant Endocrine Therapy Trials.Predictive value and clinical utility of centrally assessed ER, PgR, and Ki-67 to select adjuvant endocrine therapy for premenopausal women with hormone receptor-positive, HER2-negative early breast cancer: TEXT and SOFT trials.Quality of life and quality-adjusted survival (Q-TWiST) in patients receiving dose-intensive or standard dose chemotherapy for high-risk primary breast cancer.Duration of adjuvant chemotherapy for breast cancer: a joint analysis of two randomised trials investigating three versus six courses of CMF.Prognostic and predictive impact of central necrosis and fibrosis in early breast cancer: results from two International Breast Cancer Study Group randomized trials of chemoendocrine adjuvant therapy.Highlights from the 13th St Gallen International Breast Cancer Conference 2013. Access to innovation for patients with breast cancer: how to speed it up?Management of advanced breast cancer.Adjuvant Tamoxifen Plus Ovarian Function Suppression Versus Tamoxifen Alone in Premenopausal Women With Early Breast Cancer: Patient-Reported Outcomes in the Suppression of Ovarian Function Trial.Preoperative bevacizumab combined with letrozole and chemotherapy in locally advanced ER- and/or PgR-positive breast cancer: clinical and biological activity.Annual Hazard Rates of Recurrence for Breast Cancer During 24 Years of Follow-Up: Results From the International Breast Cancer Study Group Trials I to V.Research issues affecting preoperative systemic therapy for operable breast cancer.Absolute Benefit of Adjuvant Endocrine Therapies for Premenopausal Women With Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Early Breast Cancer: TEXT and SOFT Trials.Treatment Adherence and Its Impact on Disease-Free Survival in the Breast International Group 1-98 Trial of Tamoxifen and Letrozole, Alone and in Sequence.Tumor-infiltrating lymphocytes (TILs) are a powerful prognostic marker in patients with triple-negative breast cancer enrolled in the IBCSG phase III randomized clinical trial 22-00.Adjuvant treatment of premenopausal women with endocrine-responsive early breast cancer: design of the TEXT and SOFT trials.Symptoms of endocrine treatment and outcome in the BIG 1-98 study.
P50
Q30438696-1F3045AF-297C-4461-AC3B-497AB53D44DEQ33499393-F9D04A2D-2833-4454-B658-6687B022AC75Q33892778-ADFB3063-F7D5-4AE5-AE49-01A6CE58AE52Q33966418-ED94DB48-FFE2-499C-84B3-2142F80F1DA9Q34173001-10864F12-3DE4-4FFD-90B5-6BB35B53AFCBQ34315684-55DCC01F-7180-498C-B453-E11CA9B04E73Q34351173-596EF1DC-96F8-423D-9D17-8DEFE7F0FDB7Q34877463-AFB6254C-43E9-486A-895B-F98CCE210EE9Q35060441-971DFC21-2426-40E8-B401-72C2FC9B563DQ35135718-76E513EB-989D-4B45-A2EB-1022F9517042Q35185103-4F6ABB25-64D9-4297-A733-FC4156F292AAQ35230269-BE40D002-7C2C-48C1-89D6-EA700BFD30F1Q35230273-0EBF94DA-5AF3-4C59-843D-A76F71904B1AQ35601629-0F16B668-79FB-4497-9AB7-3AE93EC5043BQ35717509-400A06D3-F64E-46B6-AB4D-9D4CFE50A7D4Q35820247-B46C0F7B-60CC-4A5D-986D-5EC0056B0E1CQ35831869-6F48286C-863C-4684-8278-CADD4FEA27DAQ35848919-6F9593AD-DE22-4AFB-B009-D08F2BB22483Q35946515-F9566C3B-B6D1-44C3-AD66-119CCC2820EDQ36036025-E14F8AFE-E641-4E9F-B81D-A874436355F4Q36057458-B6D3646E-4E6C-4203-83DC-1F9C266D3AD8Q36065497-26EC84D1-AD6D-465E-A9D3-263BD6AFCD27Q36316636-E3D6D555-BC84-4D86-AE82-932AE2969D45Q36368902-E1BD9920-FA21-4DE3-B97D-E37B1B74E02BQ36413980-FCD02C7D-E538-4DB4-9A84-37DF5FEB05F8Q36568213-65218CD3-8E67-479A-8D6D-2CCA7FAD2B1EQ36608806-242A6F81-A140-4BB6-80B4-B39CFC6D5A0FQ36644559-AE537A7D-2D72-47B2-81A5-C8C495E1B5A1Q36658463-53F462A5-9E22-411E-86EA-7FA4B4D97A7EQ36755089-8276A685-CF18-44F2-A08A-3A35266CC907Q36860226-127693FD-730F-43ED-90EE-D21B5E1390E7Q36915190-3E603830-F217-42E9-81F6-F8B08324C716Q36977587-020F17A7-6098-4369-AC65-ED1759031E47Q37065597-BBA91290-B824-4C1A-A3EF-E746E5FE277CQ37079622-F798DBB4-41C7-4E9F-B394-14B9993CEF19Q37130142-AEC02CF2-40FC-4A3A-B7E1-E74607047F45Q37130218-D5CFECCB-8331-462A-965D-336B0F340576Q37160109-86D0861C-A67F-4851-B460-7D7FF29D4856Q37373717-FA80EBBE-14A9-42FA-9FA2-71BC128539F7Q37553885-40E43C3F-2779-4D1D-B8E1-EFD3AD71912A
P50
description
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Marco Colleoni
@ast
Marco Colleoni
@en
Marco Colleoni
@es
Marco Colleoni
@nl
type
label
Marco Colleoni
@ast
Marco Colleoni
@en
Marco Colleoni
@es
Marco Colleoni
@nl
prefLabel
Marco Colleoni
@ast
Marco Colleoni
@en
Marco Colleoni
@es
Marco Colleoni
@nl
P106
P1153
7004815101
P21
P31
P496
0000-0002-5743-3013